Pinpointing prognostic indicators of fungal infections in transplant patients

Future Microbiology

Volumn 4, Issue 1, 2009, Pages 77-84

  Baddley, John W ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Aspergillus; Candida; Mortality; Prognostic factors; Transplant

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CORTICOSTEROID; CREATINE; VORICONAZOLE;

ASPERGILLOSIS; CANDIDEMIA; CREATININE BLOOD LEVEL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HYPERBILIRUBINEMIA; INVASIVE CANDIDIASIS; LUNG DISEASE; MYCOSIS; NEUTROPENIA; NONMYELOABLATIVE CONDITIONING; ORGAN TRANSPLANTATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURGICAL MORTALITY; CANDIDIASIS; FUNGEMIA; MORTALITY; RISK FACTOR; STEM CELL TRANSPLANTATION;

ASPERGILLOSIS; CANDIDIASIS; FUNGEMIA; HUMANS; MYCOSES; ORGAN TRANSPLANTATION; PROGNOSIS; RISK FACTORS; STEM CELL TRANSPLANTATION;

ASPERGILLUS; CANDIDA;

EID: 61749099042     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.4.1.77     Document Type: Review

References (40)

1. Maschmeyer G, Haas A, Cornely OA: Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 67(11), 1567-1601 (2007).
2. Marr KA, Carter RA, Crippa F, Wald A, Corey L: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34(7), 909-917 (2002).
3. Singh N: Fungal infections in the recipients of solid organ transplantation. Infect. Dis. Clin. North Am. 17(1), 113-134 (2003).
4. Pagano L, Caira M, Nosari A et al.: Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study: Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin. Infect. Dis. 45(9), 1161-1170 (2007).
5. Barnes PD: Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br. J. Haematol. 139(19), 519-531 (2007).
6. Silveira FP, Husain S: Fungal infections in solid organ transplantation. Med. Mycol. 45(4), 305-320 (2007).
7. Lin SJ, Schranz J, Teutsch SM: Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32(3), 358-366 (2001).
8. Nucci M, Anaissie E: Emerging fungi. Infect. Dis. Clin. North Am. 20(3), 563-579 (2006).
9. Slavin MA, Osborne B, Adams R et al.: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J. Infect. Dis. 171(6), 1545-1552 (1995).
10. Marr KA, Seidel K, Slavin MA et al.: Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 96(6), 2055-2061 (2000).
11. Ullmann AJ, Lipton JH, Vesole DH et al.: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356(4), 335-347 (2007).
12. Walsh TJ, Anaissie EJ, Denning DW et al.: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46(3), 327-360 (2008).
13. Singh N, Limaye AP, Forrest G et al.: Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81(3), 320-326 (2006).
14. Lewis RE, Kontoyiannis DP: Rationale for combination antifungal therapy. Pharmacotherapy 21(8 Pt 2), 149S-164S (2001).
15. Ribaud P, Chastang C, Latge JP et al.: Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin. Infect. Dis. 28(2), 322-330 (1999).
16. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA: Invasive aspergillosis following hematopoietic cell transplantation: outcomes. and prognostic factors associated with mortality. Clin. Infect. Dis. 44(4), 531-540 (2007).
17. Cordonnier C, Ribaud P, Herbrecht R et al.: Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin. Infect. Dis. 42(7), 955-963 (2006).
18. Baddley JW, Marr KA, Andes DR et al.: Factors influencing mortality in transplant recipients with invasive aspergillosis. Presented at: 42nd Infectious Diseases Society of America Conference. Boston, MA, USA, 30 September-3 October 2004.
19. Baddley JW, Andes DR, Anaissie EJ et al.: Factors associated with mortality in transplant recipients with candidemia: results from the transplant associated infection surveillance network (TRANSNET). Presented at: 45th Infectious Diseases Society of America Conference. San Diego, CA, USA, 4-8 October 2007.
20. Nivoix Y, Velten M, Letscher-Bru V et al.: Factors associated with overall and attributable mortality in invasive aspergillosis. Clin. Infect. Dis. 47, 1176-1184 (2008).
21. Pappas PG, Rex JH, Lee J et al.: A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37(5), 634-643 (2003).
22. Segal BH, Herbrecht R, Stevens DA et al.: Defining responses to therapy and outcomes in clinical trials of invasive fungal diseases: Mycoses study group and European Organization for Research and Treatment of Cancer Criteria. Clin. Infect. Dis. 47(1), 674-683 (2008).
23. Mora-Duarte J, Betts R, Rotstein C et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347(25), 2020-2029 (2002).
24. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R: Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 112(10), 2309-2312 (2008).
25. Minari A, Husni R, Avery RK et al.: The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl. Infect. Dis. 4(4), 195-200 (2002).
26. Ascioglu S, Rex JH, de Pauw B et al.: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34(1), 7-14 (2002).
27. Goodman JL, Winston DJ, Greenfield RA et al.: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326(13), 845-851 (1992).
28. Patterson JE: Epidemiology of fungal infections in solid organ transplant patients. Transpl. Infect. Dis. 1(4), 229-236 (1999).
29. Falagas ME, Apostolou KE, Pappas VD: Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur. J. Clin. Microbiol. Infect. Dis. 25(7), 419-425 (2006).
30. Marr KA, Seidel K, White TC, Bowden RA: Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis. 181(1), 309-316 (2000).
31. Jantunen E, Salonen J, Juvonen E et al.: Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur. J. Haematol. 73(3), 174-178 (2004).
32. Uzun O, Anaissie EJ: Predictors of outcome in cancer patients with candidemia. Ann. Oncol. 11(12), 1517-1521 (2000).
33. Cheng YR, Lin LC, Young TG, Liu CE, Chen CH, Tsay RW: Risk factors for candidemia-related mortality at a medical center in central Taiwan. J. Microbiol. Immunol. Infect. 39(2), 155-161 (2006).
34. Bassetti M, Trecarichi EM, Righi E et al.: Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn. Microbiol. Infect. Dis. 58(3), 325-331 (2007).
35. Alonso-Valle H, Acha O, Garcia-Palomo JD, Farinas-Alvarez C, Fernandez-Mazarrasa C, Farinas MC: Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur. J. Clin. Microbiol. Infect. Dis. 22(4), 254-257 (2003).
36. Nolla-Salas J, Sitges-Serra A, Leon-Gil C et al.: Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med. 23(1), 23-30 (1997).
37. Baddley JW, Patel M, Bhavnani SM, Moser SA, Andes DR: Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob. Agents Chemother. 52(9), 3022-3028 (2008).
38. Pagano L, Caira M, Candoni A et al.: The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91(8), 1068-1075 (2006).
39. Nieto-Rodriguez JA, Kusne S, Manez R et al.: Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann. Surg. 223(1), 70-76 (1996).
40. Husain S, Tollemar J, Dominguez EA et al.: Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 75(12), 2023-2029 (2003).